Regeneron (REGN) Stock Forecast & Price Target

Compare

4,836 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

REGN Analyst Ratings

Moderate Buy

18 Buy

6 Hold

1 Sell

Based on 25 analysts giving stock ratings to

Regeneron

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

REGN Stock 12 Month Forecast

Average Price Target

$722.09

▲(25.82% Upside)

Based on 25 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is $722.09 with a high forecast of $890.00 and a low forecast of $543.00. The average price target represents a 25.82% change from the last price of $573.91.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"489":"$489","1180":"$1,180","661.75":"$661.8","834.5":"$834.5","1007.25":"$1,007.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":890,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$890.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":722.09,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$722.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":543,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$543.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[489,661.75,834.5,1007.25,1180],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,558.02,583.5569230769231,609.0938461538461,634.6307692307693,660.1676923076923,685.7046153846154,711.2415384615384,736.7784615384616,762.3153846153846,787.8523076923077,813.3892307692307,838.9261538461539,864.4630769230769,{"y":890,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,558.02,570.6407692307693,583.2615384615384,595.8823076923077,608.503076923077,621.1238461538461,633.7446153846154,646.3653846153846,658.9861538461539,671.6069230769231,684.2276923076923,696.8484615384616,709.4692307692308,{"y":722.09,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,558.02,556.8646153846154,555.7092307692308,554.5538461538462,553.3984615384616,552.243076923077,551.0876923076924,549.9323076923076,548.776923076923,547.6215384615384,546.4661538461538,545.3107692307692,544.1553846153846,{"y":543,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1088.47,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1179.63,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1042.44,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":840,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":759.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":709.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":670.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":696.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":615.16,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":588.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":490.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":534.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":558.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$890.00

Average Price Target$722.09

Lowest Price Target$543.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

William Pickering

Bernstein

$750→$753

Buy

31.21%

Upside

Reiterated

08/18/25

Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Stoke Therapeutics (NASDAQ: STOK) and Regeneron (NASDAQ: REGN)

Simon Baker CFA

Redburn Atlantic

$890

Buy

55.08%

Upside

Initiated

08/14/25

Regeneron (REGN) Gets a Buy from Redburn Atlantic

Tyler Van Buren

TD Cowen

$780

Buy

35.91%

Upside

Reiterated

08/14/25

TD Cowen Reaffirms Their Buy Rating on Regeneron (REGN)

Dex Genotek

TR | OpenAI - 4o

$603→$623

Buy

8.55%

Upside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Carter Gould

Cantor Fitzgerald

$678

Buy

18.14%

Upside

Reiterated

08/13/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Regeneron (REGN)Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $678.00 price target on Regeneron Pharma (NASDAQ: REGN).

Srikripa Devarakonda

Truist Financial

$940→$812

Buy

41.49%

Upside

Reiterated

08/11/25

Truist Financial Reaffirms Their Buy Rating on Regeneron (REGN)

David Risinger

Leerink Partners

$645

Buy

12.39%

Upside

Reiterated

08/06/25

Leerink Partners Reaffirms Their Buy Rating on Regeneron (REGN)Leerink Partners analyst Andrew Berens reiterated an Outperform rating and $645.00 price target on Regeneron Pharma (NASDAQ: REGN).

Cory Kasimov

Evercore ISI

$900→$750

Buy

30.68%

Upside

Reiterated

08/04/25

Evercore ISI Reaffirms Their Buy Rating on Regeneron (REGN)

Trung Huynh

UBS

$584→$595

Hold

3.67%

Upside

Reiterated

08/04/25

UBS Reaffirms Their Hold Rating on Regeneron (REGN)

Tim Anderson

Bank of America Securities

$504→$543

Sell

-5.39%

Downside

Reiterated

08/04/25

Cautious Outlook on Regeneron Despite Strong Performance: Sell Rating Due to Potential Eylea Erosion and Medicare Risks

Terence Flynn

Morgan Stanley

$754→$761

Buy

32.60%

Upside

Reiterated

08/04/25

Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Eli Lilly & Co (NYSE: LLY) and Avantor (NYSE: AVTR)

Evan Seigerman

BMO Capital

$600→$640

Buy

11.52%

Upside

Reiterated

08/04/25

Regeneron price target raised to $640 from $600 at BMO CapitalRegeneron price target raised to $640 from $600 at BMO Capital

Geoff Meacham

Citi

―

Buy

―

Reiterated

08/04/25

Regeneron (REGN) Receives a Buy from Citi

John Newman

Canaccord Genuity

$850

Buy

48.11%

Upside

Reiterated

08/04/25

Positive Indicators and Strategic Investments Support Buy Rating for Regeneron

Yatin Suneja

Guggenheim

$810→$815

Buy

42.01%

Upside

Reiterated

08/03/25

Regeneron price target raised to $815 from $810 at GuggenheimRegeneron price target raised to $815 from $810 at Guggenheim

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

William Pickering

Bernstein

$750→$753

Buy

31.21%

Upside

Reiterated

08/18/25

Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Stoke Therapeutics (NASDAQ: STOK) and Regeneron (NASDAQ: REGN)

Simon Baker CFA

Redburn Atlantic

$890

Buy

55.08%

Upside

Initiated

08/14/25

Regeneron (REGN) Gets a Buy from Redburn Atlantic

Tyler Van Buren

TD Cowen

$780

Buy

35.91%

Upside

Reiterated

08/14/25

TD Cowen Reaffirms Their Buy Rating on Regeneron (REGN)

Dex Genotek

TR | OpenAI - 4o

$603→$623

Buy

8.55%

Upside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Carter Gould

Cantor Fitzgerald

$678

Buy

18.14%

Upside

Reiterated

08/13/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Regeneron (REGN)Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $678.00 price target on Regeneron Pharma (NASDAQ: REGN).

Srikripa Devarakonda

Truist Financial

$940→$812

Buy

41.49%

Upside

Reiterated

08/11/25

Truist Financial Reaffirms Their Buy Rating on Regeneron (REGN)

David Risinger

Leerink Partners

$645

Buy

12.39%

Upside

Reiterated

08/06/25

Leerink Partners Reaffirms Their Buy Rating on Regeneron (REGN)Leerink Partners analyst Andrew Berens reiterated an Outperform rating and $645.00 price target on Regeneron Pharma (NASDAQ: REGN).

Cory Kasimov

Evercore ISI

$900→$750

Buy

30.68%

Upside

Reiterated

08/04/25

Evercore ISI Reaffirms Their Buy Rating on Regeneron (REGN)

Trung Huynh

UBS

$584→$595

Hold

3.67%

Upside

Reiterated

08/04/25

UBS Reaffirms Their Hold Rating on Regeneron (REGN)

Tim Anderson

Bank of America Securities

$504→$543

Sell

-5.39%

Downside

Reiterated

08/04/25

Cautious Outlook on Regeneron Despite Strong Performance: Sell Rating Due to Potential Eylea Erosion and Medicare Risks

Terence Flynn

Morgan Stanley

$754→$761

Buy

32.60%

Upside

Reiterated

08/04/25

Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Eli Lilly & Co (NYSE: LLY) and Avantor (NYSE: AVTR)

Evan Seigerman

BMO Capital

$600→$640

Buy

11.52%

Upside

Reiterated

08/04/25

Regeneron price target raised to $640 from $600 at BMO CapitalRegeneron price target raised to $640 from $600 at BMO Capital

Geoff Meacham

Citi

―

Buy

―

Reiterated

08/04/25

Regeneron (REGN) Receives a Buy from Citi

John Newman

Canaccord Genuity

$850

Buy

48.11%

Upside

Reiterated

08/04/25

Positive Indicators and Strategic Investments Support Buy Rating for Regeneron

Yatin Suneja

Guggenheim

$810→$815

Buy

42.01%

Upside

Reiterated

08/03/25

Regeneron price target raised to $815 from $810 at GuggenheimRegeneron price target raised to $815 from $810 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Regeneron

1 Month

xxx

Success Rate

11/17 ratings generated profit

Average Return

+0.70%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.71% of your transactions generating a profit, with an average return of +0.70% per trade.

3 Months

xxx

Success Rate

14/24 ratings generated profit

Average Return

+2.12%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +2.12% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

17/24 ratings generated profit

Average Return

+11.03%

reiterated a buy rating 14 days ago

Copying David Risinger's trades and holding each position for 1 Year would result in 70.83% of your transactions generating a profit, with an average return of +11.03% per trade.

2 Years

xxx

Success Rate

17/24 ratings generated profit

Average Return

+12.26%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 70.83% of your transactions generating a profit, with an average return of +12.26% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

REGN Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, REGN has received 52 Buy Ratings, 10 Hold Ratings, and 3 Sell Ratings. REGN average Analyst price target in the past 3 months is 722.09.

Each month's total comprises the sum of three months' worth of ratings.

REGN Financial Forecast

REGN Earnings Forecast

Next quarter’s earnings estimate for REGN is $9.67 with a range of $7.61 to $11.31. The previous quarter’s EPS was $12.89. REGN beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.20% of the time in the same period. In the last calendar year REGN has Outperformed its overall industry.

REGN Sales Forecast

Next quarter’s sales forecast for REGN is $3.57B with a range of $3.39B to $3.80B. The previous quarter’s sales results were $3.68B. REGN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.29% of the time in the same period. In the last calendar year REGN has Outperformed its overall industry.

REGN Stock Forecast FAQ

What is REGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Regeneron Pharmaceuticals’s 12-month average price target is 722.09.

What is REGN’s upside potential, based on the analysts’ average price target?

Regeneron Pharmaceuticals has 25.82% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is REGN a Buy, Sell or Hold?

Regeneron Pharmaceuticals has a consensus rating of Moderate Buy which is based on 18 buy ratings, 6 hold ratings and 1 sell ratings.

What is Regeneron Pharmaceuticals’s price target?

The average price target for Regeneron Pharmaceuticals is 722.09. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $890.00 ,the lowest forecast is $543.00. The average price target represents 25.82% Increase from the current price of $573.91.

What do analysts say about Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 25 Wall Streets Analysts.

How can I buy shares of REGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Regeneron (REGN) Stock Forecast & Price Target

REGN Analyst Ratings

REGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Regeneron

REGN Analyst Recommendation Trends

REGN Financial Forecast

REGN Earnings Forecast

REGN Sales Forecast

REGN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts